Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; calcium carbonate; fumaric acid; mannitol; hyprolose - treatment of erectile dysfunction in adult males.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; fumaric acid; calcium carbonate; hyprolose; iron oxide yellow - treatment of erectile dysfunction in adult males.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 1.257 mg (equivalent: fentanyl, qty 800 microgram) - tablet - excipient ingredients: mannitol; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 0.9426 mg (equivalent: fentanyl, qty 600 microgram) - tablet - excipient ingredients: mannitol; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 0.4713 mg (equivalent: fentanyl, qty 300 microgram) - tablet - excipient ingredients: mannitol; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 10 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 2 mg - capsule, hard - excipient ingredients: titanium dioxide; gelatin; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 0.6248 mg (equivalent: fentanyl, qty 400 microgram) - tablet - excipient ingredients: mannitol; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - fentanyl citrate, quantity: 0.3142 mg (equivalent: fentanyl, qty 200 microgram) - tablet - excipient ingredients: mannitol; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose - abstral is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.